Identification

Name
Metoclopramide
Accession Number
DB01233  (APRD00665)
Type
Small Molecule
Groups
Approved, Investigational
Description

A dopamine D2 antagonist that is used as an antiemetic.

Structure
Thumb
Synonyms
  • 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide
  • 2-methoxy-5-chloroprocainamide
  • 4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide
  • 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
  • Metoclopramida
  • Metoclopramidum
Product Ingredients
IngredientUNIICASInChI Key
Metoclopramide hydrochloride7B1QZY5SWZ7232-21-5RVFUNJWWXKCWNS-UHFFFAOYSA-N
Metoclopramide hydrochloride monohydrateW1792A2RVD54143-57-6KJBLQGHJOCAOJP-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Maxeran 5mg TabTablet5 mgOralLabs Nordic Laboratories Inc. Subsidary Of M.M.D.C.1984-12-311998-08-12Canada
Maxeran LiqLiquid1 mgOralHoechst Marion Roussel1995-12-312000-07-28Canada
Maxeran-10 (10mg Tablet)Tablet10 mgOralHoechst Marion Roussel1995-12-312000-07-28Canada
Maxeran-5 (5mg Tablet)Tablet5 mgOralHoechst Marion Roussel1996-10-232000-07-28Canada
MetoclopramideInjection, solution5 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-05-01Not applicableUs
MetoclopramideInjection, solution10 mg/2mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-08-012017-01-27Us
MetoclopramideInjection, solution5 mg/mLIntramuscular; IntravenousCardinal Health2010-12-092017-12-22Us
Metoclopramide Hydrochloride InjectionLiquid5 mgIntramuscular; IntravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
Metoclopramide Hydrochloride Injection HsLiquid5 mgIntravenousBioniche Pharma (Canada) Ltd1999-04-192014-09-11Canada
Metoclopramide OmegaLiquid5 mgIntramuscular; IntravenousOmega Laboratories Ltd2001-04-30Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-metoclop Tab 10mgTablet10 mgOralApotex Corporation1989-12-31Not applicableCanada
Apo-metoclop Tab 5mgTablet5 mgOralApotex Corporation1989-12-31Not applicableCanada
MetoclopramideTablet5 mg/1OralCarilion Materials Management1993-07-01Not applicableUs
MetoclopramideTablet10 mg/1OralNucare Pharmaceuticals, Inc.1990-09-30Not applicableUs
MetoclopramideTablet5 mg/1OralPhysicians Total Care, Inc.2003-03-27Not applicableUs
MetoclopramideTablet5 mg/1OralNucare Pharmaceuticals, Inc.1993-07-01Not applicableUs
MetoclopramideSolution5 mg/5mLOralCardinal Health1991-06-01Not applicableUs
MetoclopramideTablet10 mg/1OralActavis Elizabeth LLC1985-10-172017-07-22Us
MetoclopramideTablet10 mg/1OralMc Kesson Contract Packaging2013-03-142018-03-09Us
MetoclopramideTablet5 mg/1OralRanbaxy Inc.2009-03-13Not applicableUs63304 0845 01 nlmimage10 fb08fd97
International/Other Brands
Cerucal / Degan / Elieten / Maxeran / Maxolon / METOZOLV / Plasil1 / Plazilin / Pramin / Primperan / Pulin / Pylomid / Reliveran
Categories
UNII
L4YEB44I46
CAS number
364-62-5
Weight
Average: 299.796
Monoisotopic: 299.14005467
Chemical Formula
C14H22ClN3O2
InChI Key
TTWJBBZEZQICBI-UHFFFAOYSA-N
InChI
InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
IUPAC Name
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
SMILES
CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC

Pharmacology

Indication

For the treatment of gastroesophageal reflux disease (GERD). It is also used in treating nausea and vomiting, and to increase gastric emptying.

Associated Conditions
Associated Therapies
Pharmacodynamics

Metoclopramide, although chemically related to procainamide, does not possess local anesthetic or antiarrhythmic properties. Metoclopramide is used to enhance GI motility, to treat diabetic gastroparesis, as an antinauseant, and to facilitate intubation of the small bowel during radiologic examination. Metoclopramide may be used to treat chemotherapy-induced emesis and as a radiosensitizing agents in the treatment of non-small cell lung carcinoma and glioblastomas in the future.

Mechanism of action

Metoclopramide inhibits gastric smooth muscle relaxation produced by dopamine, therefore increasing cholinergic response of the gastrointestinal smooth muscle. It accelerates intestinal transit and gastric emptying by preventing relaxation of gastric body and increasing the phasic activity of antrum. Simultaneously, this action is accompanied by relaxation of the upper small intestine, resulting in an improved coordination between the body and antrum of the stomach and the upper small intestine. Metoclopramide also decreases reflux into the esophagus by increasing the resting pressure of the lower esophageal sphincter and improves acid clearance from the esophagus by increasing amplitude of esophageal peristaltic contractions. Metoclopramide's dopamine antagonist action raises the threshold of activity in the chemoreceptor trigger zone and decreases the input from afferent visceral nerves. Studies have also shown that high doses of metoclopramide can antagonize 5-hydroxytryptamine (5-HT) receptors in the peripheral nervous system in animals.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
AMuscarinic acetylcholine receptor M1
agonist
Human
U5-hydroxytryptamine receptor 4
agonist
Human
U5-hydroxytryptamine receptor 3A
agonist
Human
UAcetylcholinesterase
inhibitor
Human
Absorption

Rapidly and well absorbed (oral bioavailability 80±15.5%).

Volume of distribution
  • 4.4±0.65 L/kg
Protein binding

30%

Metabolism

Hepatic

Route of elimination

Approximately 85% of the radioactivity of an orally administered dose appears in the urine within 72 hours.

Half life

5-6 hr

Clearance
  • 0.67 +/- 0.14 L/hr/kg [infants (0.9-5.4 months) with gastroesophageal reflux (GER)]
Toxicity

Oral, mouse LD50: 280 mg/kg. Signs of overdose include drowsiness, disorientation, and extrapyramidal reactions.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Potassium voltage-gated channel subfamily H member 2---(C;C) / (A;C)A > CEffect Directly StudiedThe presence of this polymorphism in KCNH2 may be associated with increased clinical efficacy with metoclopramide.Details
Alpha-1D adrenergic receptor---(T;T) / (A;T)A > TEffect Directly StudiedThe presence of this polymorphism in ADRA1D may be associated with increased clinical efficacy with metoclopramide.Details
Cytochrome P450 2D6CYP2D6*2A(G;G) / (C;G)C > GADR Directly StudiedPatients with this genotype have reduced metabolism of metoclopramide and may be at a higher risk of experiencing adverse events.Details
Cytochrome P450 2D6CYP2D6*2(A;A) / (A;G)G > AADR Directly StudiedPatients with this genotype have reduced metabolism of metoclopramide and may be at a higher risk of experiencing adverse events.Details
Cytochrome P450 2D6CYP2D6*4(A;A) / (A;G)G > ADirectly Studied EffectPatients with this genotype have reduced metabolism of metoclopramide.Details
Potassium voltage-gated channel subfamily H member 2---(T;T) / (C;T)G > AADR Directly StudiedThe presence of this polymorphism in KCNH2 is associated with higher incidences of adverse events from metoclopramide treatment.Details
Multidrug resistance protein 1---(T;T) / (C;T) / (T;T) / (G;T) / (T;T) / (C;T)T Allele / G > T  … show all Effect Directly StudiedPatients with this polymorphism in ABCB1 may have a reduced response to clomipramine.Details
NADH-cytochrome b5 reductase 3---Not AvailableExon 2 c.129C>A / Exon 2 c.149G>A  … show all ADR InferredRisk of methemglobinemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe therapeutic efficacy of (2-benzhydryloxyethyl)diethyl-methylammonium iodide can be decreased when used in combination with Metoclopramide.Experimental
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Metoclopramide.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbexinostatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Abexinostat.Investigational
AcebutololMetoclopramide may increase the bradycardic activities of Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aceprometazine.Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetophenazine.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Metoclopramide.Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Acrivastine.Approved
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Metoclopramide.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Alaproclate.Experimental
AlcaftadineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Alcaftadine.Approved
AlclometasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Alclometasone.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Metoclopramide.Experimental
AldosteroneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Aldosterone.Experimental, Investigational
AlfentanilThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Alfentanil.Approved, Illicit
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Metoclopramide.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Alimemazine.Approved, Vet Approved
AlimemazineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Alimemazine.Approved, Vet Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Metoclopramide.Approved, Investigational
AlphacetylmethadolThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Alphaprodine.Illicit
AlprenololMetoclopramide may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Aluminium clofibrate.Experimental
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Metoclopramide.Approved
AmcinonideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Amcinonide.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Amifampridine.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of serotonin syndrome, extrapyramidal symptoms, and neuroleptic malignant syndrome can be increased when Metoclopramide is combined with Amitriptyline.Approved
AmobarbitalThe therapeutic efficacy of Amobarbital can be decreased when used in combination with Metoclopramide.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amoxapine.Approved
AmoxapineThe risk or severity of serotonin syndrome, extrapyramidal symptoms, and neuroleptic malignant syndrome can be increased when Metoclopramide is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amperozide.Experimental
AmphetamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Amphetamine.Approved, Illicit, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Anagrelide.Approved
AnisodamineMetoclopramide may increase the bradycardic activities of Anisodamine.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Metoclopramide.Approved
AntazolineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Antazoline.Approved
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Metoclopramide.Approved, Investigational
AprobarbitalThe therapeutic efficacy of Aprobarbital can be decreased when used in combination with Metoclopramide.Approved, Illicit
ArecolineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Arecoline.Experimental
ArformoterolThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Metoclopramide.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole lauroxil.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Aripiprazole lauroxil.Approved, Investigational
ArotinololMetoclopramide may increase the bradycardic activities of Arotinolol.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Artemether.Approved
AsenapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Asenapine.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Metoclopramide.Approved, Investigational
AtenololMetoclopramide may increase the bradycardic activities of Atenolol.Approved
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Metoclopramide.Approved
AtorvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Atorvastatin.Approved
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Metoclopramide.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Metoclopramide.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Metoclopramide.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Azaperone.Investigational, Vet Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Azatadine.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Azithromycin.Approved
BarbitalThe therapeutic efficacy of Barbital can be decreased when used in combination with Metoclopramide.Illicit
Barbituric acid derivativeThe therapeutic efficacy of Barbituric acid derivative can be decreased when used in combination with Metoclopramide.Experimental, Illicit
Beclomethasone dipropionateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
BedaquilineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Bedaquiline.Approved
BefunololMetoclopramide may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Metoclopramide.Withdrawn
BenmoxinThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Benperidol.Approved, Investigational
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Metoclopramide.Approved
BenziloneThe therapeutic efficacy of Benzilone can be decreased when used in combination with Metoclopramide.Experimental
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Benzphetamine.Approved, Illicit
BenzquinamideThe therapeutic efficacy of Benzquinamide can be decreased when used in combination with Metoclopramide.Withdrawn
BepridilThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Besifloxacin.Approved
BetamethasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololMetoclopramide may increase the bradycardic activities of Betaxolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Bethanechol.Approved
BevantololMetoclopramide may increase the bradycardic activities of Bevantolol.Approved
BevoniumThe therapeutic efficacy of Bevonium can be decreased when used in combination with Metoclopramide.Experimental
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Bezafibrate.Approved, Investigational
BezitramideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Bezitramide.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Bifeprunox.Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Bilastine.Approved, Investigational
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Metoclopramide.Approved, Investigational
BisoprololMetoclopramide may increase the bradycardic activities of Bisoprolol.Approved
BL-1020The risk or severity of adverse effects can be increased when Metoclopramide is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Blonanserin.Approved, Investigational
BlonanserinThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Blonanserin.Approved, Investigational
BopindololMetoclopramide may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Metoclopramide.Experimental
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Metoclopramide.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Brexpiprazole.Approved, Investigational
BrexpiprazoleThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Brexpiprazole.Approved, Investigational
BrofaromineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Brofaromine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metoclopramide.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Bromperidol.Approved, Investigational
BrompheniramineThe therapeutic efficacy of Brompheniramine can be decreased when used in combination with Metoclopramide.Approved
BucindololMetoclopramide may increase the bradycardic activities of Bucindolol.Investigational
BuclizineThe therapeutic efficacy of Buclizine can be decreased when used in combination with Metoclopramide.Approved
BudesonideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Budesonide.Approved
BufuralolMetoclopramide may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololMetoclopramide may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe therapeutic efficacy of Bupropion can be decreased when used in combination with Metoclopramide.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Buserelin.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Metoclopramide.Approved, Investigational
ButabarbitalThe therapeutic efficacy of Butabarbital can be decreased when used in combination with Metoclopramide.Approved, Illicit
ButalbitalThe therapeutic efficacy of Butalbital can be decreased when used in combination with Metoclopramide.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Butaperazine.Experimental
ButethalThe therapeutic efficacy of Butethal can be decreased when used in combination with Metoclopramide.Approved, Illicit
ButorphanolThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Metoclopramide.Approved, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Metoclopramide.Approved
CamylofinThe therapeutic efficacy of Camylofin can be decreased when used in combination with Metoclopramide.Experimental
CannabidiolThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Cannabidiol.Approved, Investigational
CarbamazepineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Carbamazepine.Approved, Investigational
CarbamoylcholineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Carbamoylcholine.Approved
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Cariprazine.Approved, Investigational
CariprazineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Cariprazine.Approved, Investigational
CaroxazoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Caroxazone.Withdrawn
CarteololMetoclopramide may increase the bradycardic activities of Carteolol.Approved
CarvedilolMetoclopramide may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololMetoclopramide may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ceritinib.Approved
CerivastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Cerivastatin.Approved, Withdrawn
CetirizineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Cetirizine.Approved
CevimelineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Cevimeline.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Chlorcyclizine.Approved
ChloroprocaineThe therapeutic efficacy of Chloroprocaine can be decreased when used in combination with Metoclopramide.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metoclopramide.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Metoclopramide.Withdrawn
ChlorphentermineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpromazineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Metoclopramide.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorprothixeneThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Metoclopramide.Approved, Investigational, Withdrawn
CiclesonideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ciclesonide.Approved, Investigational
CilostazolThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Cilostazol.Approved, Investigational
CinitaprideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Cinitapride.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Cinnarizine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Ciprofibrate.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe therapeutic efficacy of Cisatracurium can be decreased when used in combination with Metoclopramide.Approved
CitalopramThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Clemastine.Approved, Investigational
ClidiniumThe therapeutic efficacy of Clidinium can be decreased when used in combination with Metoclopramide.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clindamycin.Approved, Vet Approved
ClobetasolThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Clobetasol.Approved, Investigational
Clobetasol propionateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Clobetasol propionate.Approved
ClobetasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Clobetasone.Approved
ClocortoloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Clocortolone.Approved
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Clofibride.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clopenthixol.Experimental
CloprednolThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Cloprednol.Experimental
CloranololMetoclopramide may increase the bradycardic activities of Cloranolol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clozapine.Approved
ClozapineThe therapeutic efficacy of Clozapine can be decreased when used in combination with Metoclopramide.Approved
CocaineThe therapeutic efficacy of Cocaine can be decreased when used in combination with Metoclopramide.Approved, Illicit
CodeineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Codeine.Approved, Illicit
CorticotropinThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
CortivazolThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Cortivazol.Investigational
CrizotinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with CUDC-907.Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Cyamemazine.Approved
CyclizineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Cyclizine.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Metoclopramide.Approved
CyclosporineMetoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational, Vet Approved
CycrimineThe therapeutic efficacy of Cycrimine can be decreased when used in combination with Metoclopramide.Approved
CyproheptadineThe therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Metoclopramide.Approved
DabrafenibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dabrafenib.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dapoxetine.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Metoclopramide.Approved, Investigational
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Metoclopramide.Approved, Investigational
DasatinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dasatinib.Approved, Investigational
DeflazacortThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Deflazacort.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Degarelix.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Delamanid.Approved, Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Metoclopramide.Approved
DesipramineThe risk or severity of serotonin syndrome, extrapyramidal symptoms, and neuroleptic malignant syndrome can be increased when Metoclopramide is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Desloratadine.Approved, Investigational
DesonideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Desonide.Approved, Investigational
DesoximetasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Desoximetasone.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desvenlafaxine.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dexbrompheniramine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dexchlorpheniramine maleate.Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Metoclopramide.Withdrawn
DexfenfluramineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dexfenfluramine.Approved, Illicit, Investigational, Withdrawn
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Metoclopramide.Approved, Investigational
DextroamphetamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Metoclopramide.Approved
DextromoramideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dezocine.Approved, Investigational
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Metoclopramide.Approved
DiethylpropionThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Diethylpropion.Approved, Illicit
DifemerineThe therapeutic efficacy of Difemerine can be decreased when used in combination with Metoclopramide.Experimental
DiflorasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Diflorasone.Approved
DifloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Difloxacin.Vet Approved
DifluocortoloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Difluprednate.Approved
DihexyverineThe therapeutic efficacy of Dihexyverine can be decreased when used in combination with Metoclopramide.Experimental
DihydrocodeineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Metoclopramide.Approved, Investigational
DihydroetorphineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dimenhydrinate.Approved
DimethyltryptamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dimethyltryptamine.Experimental, Illicit
DimetindeneThe therapeutic efficacy of Dimetindene can be decreased when used in combination with Metoclopramide.Approved, Investigational
DiphemanilThe therapeutic efficacy of Diphemanil can be decreased when used in combination with Metoclopramide.Experimental
Diphemanil MethylsulfateThe therapeutic efficacy of Diphemanil Methylsulfate can be decreased when used in combination with Metoclopramide.Approved, Vet Approved, Withdrawn
DiphenhydramineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Metoclopramide.Approved, Investigational
DiphenidolThe therapeutic efficacy of Diphenidol can be decreased when used in combination with Metoclopramide.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dipyridamole.Approved
DisopyramideThe therapeutic efficacy of Disopyramide can be decreased when used in combination with Metoclopramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dixyrazine.Experimental
DofetilideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Dolasetron.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Donepezil.Approved
DosulepinThe risk or severity of serotonin syndrome, extrapyramidal symptoms, and neuroleptic malignant syndrome can be increased when Metoclopramide is combined with Dosulepin.Approved
DoxacuriumThe therapeutic efficacy of Doxacurium can be decreased when used in combination with Metoclopramide.Approved
DoxepinThe risk or severity of serotonin syndrome, extrapyramidal symptoms, and neuroleptic malignant syndrome can be increased when Metoclopramide is combined with Doxepin.Approved, Investigational
DoxylamineThe therapeutic efficacy of Doxylamine can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
DPDPEThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with DPDPE.Experimental
DronedaroneThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Droperidol.Approved, Vet Approved
DuloxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Duloxetine.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ebastine.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ecopipam.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Metoclopramide.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Eliglustat.Approved
EltoprazineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Eltoprazine.Investigational
EluxadolineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Eluxadoline.Approved, Investigational
EmedastineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Emedastine.Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with Metoclopramide.Experimental
EnoxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Enoxacin.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Entinostat.Investigational
EpanololMetoclopramide may increase the bradycardic activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Epibatidine.Experimental
EpinastineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Epinastine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Metoclopramide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Metoclopramide.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Metoclopramide.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololMetoclopramide may increase the bradycardic activities of Esatenolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Escitalopram.Approved, Investigational
EsmololMetoclopramide may increase the bradycardic activities of Esmolol.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with Metoclopramide.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Metoclopramide.Approved
EthylmorphineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Ethylmorphine.Approved, Illicit
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Etofibrate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Metoclopramide.Withdrawn
EtorphineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Metoclopramide.Experimental
EzogabineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ezogabine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Metoclopramide.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Metoclopramide.Approved
FenfluramineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Fenofibric acid.Approved
FenpiveriniumThe therapeutic efficacy of Fenpiverinium can be decreased when used in combination with Metoclopramide.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metoclopramide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Metoclopramide.Approved
FexofenadineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fingolimod.Approved, Investigational
FlavoxateThe therapeutic efficacy of Flavoxate can be decreased when used in combination with Metoclopramide.Approved
FlecainideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fleroxacin.Approved
FlibanserinThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluanisone.Experimental
FlucloroloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluclorolone.Experimental
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Metoclopramide.Approved, Investigational
FludrocortisoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Flumequine.Withdrawn
FlumethasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Flumethasone.Approved, Vet Approved
FlunisolideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluocinonide.Approved, Investigational
FluocortinThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluocortin.Experimental
FluocortoloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluocortolone.Approved, Withdrawn
FluorometholoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Flupentixol.Approved, Investigational, Withdrawn
FlupentixolThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Metoclopramide.Approved, Investigational, Withdrawn
FluperoloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluperolone.Experimental
FluphenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluphenazine.Approved
FluprednideneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluprednisolone.Approved
FlurandrenolideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Flurandrenolide.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluspirilene.Approved, Investigational
FluspirileneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Fluspirilene.Approved, Investigational
FluticasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluticasone furoate.Approved
Fluticasone propionateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluticasone propionate.Approved
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluvoxamine.Approved, Investigational
FormocortalThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Formocortal.Experimental
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Metoclopramide.Approved, Investigational
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Metoclopramide.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Metoclopramide.Approved, Investigational
FurazolidoneThe risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Metoclopramide.Approved, Investigational, Vet Approved
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Gadobenic acid.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Metoclopramide.Approved
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with Metoclopramide.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Metoclopramide.Approved
Gantacurium ChlorideThe therapeutic efficacy of Gantacurium Chloride can be decreased when used in combination with Metoclopramide.Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Gatifloxacin.Approved, Investigational
GemfibrozilThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Gemifloxacin.Approved, Investigational
GepefrineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Gepefrine.Experimental
GepironeThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Gepirone.Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Givinostat.Investigational
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Metoclopramide.Approved, Investigational, Vet Approved
GoserelinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Goserelin.Approved
GranisetronThe risk or severity of serotonin syndrome can be increased when Granisetron is combined with Metoclopramide.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Metoclopramide is combined with GTS-21.Investigational
HalcinonideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Halcinonide.Approved, Investigational, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Halofantrine.Approved
HalometasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Halometasone.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Haloperidol.Approved
HarmalineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Harmaline.Experimental
HeptabarbitalThe therapeutic efficacy of Heptabarbital can be decreased when used in combination with Metoclopramide.Approved
HeroinThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Metoclopramide.Experimental
HexobarbitalThe therapeutic efficacy of Hexobarbital can be decreased when used in combination with Metoclopramide.Approved
HexocycliumThe therapeutic efficacy of Hexocyclium can be decreased when used in combination with Metoclopramide.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Histrelin.Approved
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Metoclopramide.Approved
Homatropine MethylbromideThe therapeutic efficacy of Homatropine Methylbromide can be decreased when used in combination with Metoclopramide.Approved
HydracarbazineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Hydracarbazine.Experimental
HydrocodoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Hydrocodone.Approved, Illicit
HydrocortisoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
Hydrocortisone aceponateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Hydrocortisone valerate.Approved, Vet Approved
HydromorphoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Hydroxyamphetamine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Hydroxychloroquine.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Metoclopramide.Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Metoclopramide.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Metoclopramide.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ibutilide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Iloperidone.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Iloperidone.Approved
ImatinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Imatinib.Approved
ImidafenacinThe therapeutic efficacy of Imidafenacin can be decreased when used in combination with Metoclopramide.Approved, Investigational
ImipramineThe risk or severity of serotonin syndrome, extrapyramidal symptoms, and neuroleptic malignant syndrome can be increased when Metoclopramide is combined with Imipramine.Approved
IndacaterolThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Metoclopramide.Approved
IndenololMetoclopramide may increase the bradycardic activities of Indenolol.Withdrawn
Iofetamine I-123The risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Iofetamine I-123.Approved
IpratropiumThe therapeutic efficacy of Ipratropium can be decreased when used in combination with Metoclopramide.Approved
IproniazidThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Metoclopramide.Approved
IsofluraneThe therapeutic efficacy of Isoflurane can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
IsoniazidThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Isoniazid.Approved, Investigational
IsopropamideThe therapeutic efficacy of Isopropamide can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Metoclopramide.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Metoclopramide.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ivabradine.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ivosidenib.Approved, Investigational
KetanserinThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Ketanserin.Investigational
KetobemidoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Metoclopramide.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ketotifen.Approved
L-TryptophanThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Metoclopramide.Approved, Nutraceutical, Withdrawn
LabetalolMetoclopramide may increase the bradycardic activities of Labetalol.Approved
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Metoclopramide.Approved, Investigational
LandiololMetoclopramide may increase the bradycardic activities of Landiolol.Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lapatinib.Approved, Investigational
LasmiditanThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Lasmiditan.Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lenvatinib.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Leuprolide.Approved, Investigational
LevobetaxololMetoclopramide may increase the bradycardic activities of Levobetaxolol.Approved, Investigational
LevobunololMetoclopramide may increase the bradycardic activities of Levobunolol.Approved
LevocabastineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Metoclopramide.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe therapeutic efficacy of Levomethadyl Acetate can be decreased when used in combination with Metoclopramide.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Metoclopramide.Approved
LincomycinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Metoclopramide.Approved, Investigational
LisdexamfetamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Lisdexamfetamine.Approved, Investigational
LisurideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Lisuride.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lithium cation.Experimental
LobelineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lobeline.Investigational
LofentanilThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Lofentanil.Illicit
LofexidineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Lofexidine.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lomefloxacin.Approved, Investigational
LopinavirThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Loratadine.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Metoclopramide.Approved
LoteprednolThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Loteprednol.Approved
LovastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Loxapine.Approved
LoxapineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Loxapine.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lumateperone.Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.Approved, Investigational
LurasidoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Lurasidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of serotonin syndrome can be increased when Lysergic Acid Diethylamide is combined with Metoclopramide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with m-Chlorophenylpiperazine.Investigational
MacimorelinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Macimorelin.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Metoclopramide.Approved, Investigational
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with Metoclopramide.Experimental
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Metoclopramide.Approved, Investigational
MebanazineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Mebanazine.Withdrawn
MebeverineThe therapeutic efficacy of Mebeverine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MedrysoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Medrysone.Approved
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Metoclopramide.Approved, Investigational
MelengestrolThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Melengestrol.Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Melperone.Approved, Investigational
MepenzolateThe therapeutic efficacy of Mepenzolate can be decreased when used in combination with Metoclopramide.Approved
MephedroneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Mephedrone.Investigational
MephentermineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Mephentermine.Approved
MepindololMetoclopramide may increase the bradycardic activities of Mepindolol.Experimental
MeprednisoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Meprednisone.Approved, Investigational
MeptazinolThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mepyramine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mesoridazine.Approved, Investigational
MesoridazineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Metaxalone.Approved
MethacholineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Methacholine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metoclopramide.Approved
Methadyl AcetateThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Methamphetamine.Approved, Illicit
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetharbitalThe therapeutic efficacy of Metharbital can be decreased when used in combination with Metoclopramide.Withdrawn
MethotrimeprazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Methotrimeprazine.Approved, Investigational
MethotrimeprazineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MethoxyphenamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Methoxyphenamine.Experimental
MethscopolamineThe therapeutic efficacy of Methscopolamine can be decreased when used in combination with Metoclopramide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Methylene blue.Approved, Investigational
Methylene blueThe risk or severity of serotonin syndrome can be increased when Methylene blue is combined with Metoclopramide.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Metoclopramide.Approved, Investigational
MethylphenobarbitalThe therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Metoclopramide.Approved
MethylprednisoloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
Methylscopolamine bromideThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Metoclopramide.Approved
MethylthioniniumThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Methylthioninium.Experimental, Investigational
MetipranololMetoclopramide may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Metoclopramide.Approved
MetocurineThe therapeutic efficacy of Metocurine can be decreased when used in combination with Metoclopramide.Approved
Metocurine IodideThe therapeutic efficacy of Metocurine Iodide can be decreased when used in combination with Metoclopramide.Approved, Withdrawn
MetoprololMetoclopramide may increase the bradycardic activities of Metoprolol.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Metoclopramide.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Metoclopramide.Approved
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Mevastatin.Experimental
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Metoclopramide.Approved, Investigational
MidomafetamineThe risk or severity of serotonin syndrome can be increased when Midomafetamine is combined with Metoclopramide.Experimental, Illicit, Investigational
MifepristoneThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Minaprine.Approved
MirabegronThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Metoclopramide.Approved
MivacuriumThe therapeutic efficacy of Mivacurium can be decreased when used in combination with Metoclopramide.Approved
MK-212The risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with MK-212.Investigational
MMDAThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with MMDA.Experimental, Illicit
MocetinostatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Mocetinostat.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Metoclopramide.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Metoclopramide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Molindone.Approved
MometasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Mometasone.Approved, Vet Approved
Mometasone furoateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Mometasone furoate.Approved, Vet Approved
MoperoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mosapramine.Experimental
MosaprideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Mosapride.Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Moxifloxacin.Approved, Investigational
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NadololMetoclopramide may increase the bradycardic activities of Nadolol.Approved
NalbuphineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Nalbuphine.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Nalidixic Acid.Approved, Investigational
NaltrexoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Metoclopramide.Approved, Investigational
NebivololMetoclopramide may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Metoclopramide.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Nemonoxacin.Investigational
NialamideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Nialamide.Withdrawn
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Metoclopramide.Approved, Investigational
NicomorphineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Nicomorphine.Experimental
NicotineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nicotine.Approved
NilotinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Nilotinib.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Metoclopramide.Approved
Nitrous acidThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nitrous acid.Approved, Investigational
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Metoclopramide.Approved
NormethadoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of serotonin syndrome, extrapyramidal symptoms, and neuroleptic malignant syndrome can be increased when Metoclopramide is combined with Nortriptyline.Approved
NutmegThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Nutmeg.Approved
OctamoxinThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Octamoxin.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Metoclopramide.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Olanzapine.Approved, Investigational
OlanzapineThe therapeutic efficacy of Olanzapine can be decreased when used in combination with Metoclopramide.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Olodaterol.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Olopatadine.Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Metoclopramide.Approved
OpiumThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Opium.Approved, Illicit
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Orbifloxacin.Vet Approved
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Metoclopramide.Approved
OsanetantThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Osanetant.Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Metoclopramide.Experimental, Investigational
OxaliplatinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxaliplatin.Approved, Investigational
OxatomideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxatomide.Investigational
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Metoclopramide.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxolinic acid.Experimental
OxprenololMetoclopramide may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Metoclopramide.Approved, Investigational
OxycodoneThe risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Metoclopramide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Oxypertine.Experimental
OxyphencyclimineThe therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Metoclopramide.Approved
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Metoclopramide.Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Metoclopramide.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Paliperidone.Approved
PalonosetronThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Palonosetron.Approved, Investigational
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Metoclopramide.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Papaverine.Approved, Investigational
ParamethasoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Paramethasone.Approved
PargylineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paroxetine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pasireotide.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pefloxacin.Approved
PenbutololMetoclopramide may increase the bradycardic activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Penfluridol.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Metoclopramide.Approved, Vet Approved
PenthienateThe therapeutic efficacy of Penthienate can be decreased when used in combination with Metoclopramide.Experimental
PentobarbitalThe therapeutic efficacy of Pentobarbital can be decreased when used in combination with Metoclopramide.Approved, Investigational, Vet Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Metoclopramide.Approved
PerazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perazine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Perflutren.Approved
PergolideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metoclopramide.Approved
PhenazocineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Metoclopramide.Approved
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Metoclopramide.Experimental
PheniprazineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pheniprazine.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pheniramine.Approved
PhenobarbitalThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with Metoclopramide.Approved, Investigational
PhenoperidineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Metoclopramide.Approved, Illicit
PilocarpineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pilocarpine.Approved, Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pimavanserin.Approved, Investigational
PimavanserinThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pimozide.Approved
PimozideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pimozide.Approved
PindololThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipamperone.Approved, Investigational
PipamperoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pipamperone.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Metoclopramide.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pipemidic acid.Experimental
PipenzolateThe therapeutic efficacy of Pipenzolate can be decreased when used in combination with Metoclopramide.Experimental
PiperidolateThe therapeutic efficacy of Piperidolate can be decreased when used in combination with Metoclopramide.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipotiazine.Approved, Investigational
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Metoclopramide.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Metoclopramide.Investigational
PiritramideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pirlindole.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Piromidic acid.Experimental
PitavastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Pitavastatin.Approved
PitolisantThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pivhydrazine.Withdrawn
PizotifenThe therapeutic efficacy of Pizotifen can be decreased when used in combination with Metoclopramide.Approved
PoldineThe therapeutic efficacy of Poldine can be decreased when used in combination with Metoclopramide.Experimental
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Metoclopramide.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Pracinostat.Investigational
PractololMetoclopramide may increase the bradycardic activities of Practolol.Approved
PramipexoleThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Metoclopramide.Approved, Investigational
PravastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Pravastatin.Approved
PrednicarbateThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednicarbate.Approved, Investigational
PrednisoloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednisone.Approved, Vet Approved
PrednylideneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednylidene.Experimental
PrifiniumThe therapeutic efficacy of Prifinium can be decreased when used in combination with Metoclopramide.Experimental
PrilocaineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prilocaine.Approved
PrimaquineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Primaquine.Approved
PrimidoneThe therapeutic efficacy of Primidone can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Procainamide.Approved
ProcaineThe therapeutic efficacy of Procaine can be decreased when used in combination with Metoclopramide.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Metoclopramide.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.Approved, Vet Approved
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Metoclopramide.Approved
PromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promazine.Approved, Vet Approved
PromazineThe therapeutic efficacy of Promazine can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promethazine.Approved, Investigational
PropafenoneMetoclopramide may increase the bradycardic activities of Propafenone.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Metoclopramide.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Propericiazine.Approved, Investigational
PropiomazineThe therapeutic efficacy of Propiomazine can be decreased when used in combination with Metoclopramide.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Propiopromazine.Vet Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Metoclopramide.Approved, Investigational
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Metoclopramide.Approved, Investigational, Vet Approved
PropranololMetoclopramide may increase the bradycardic activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prothipendyl.Investigational
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Prulifloxacin.Investigational
PseudoephedrineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Quetiapine.Approved
QuetiapineThe therapeutic efficacy of Quetiapine can be decreased when used in combination with Metoclopramide.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Metoclopramide.Approved, Investigational
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Metoclopramide.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Raclopride.Investigational
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Metoclopramide.Approved, Investigational
RapacuroniumThe therapeutic efficacy of Rapacuronium can be decreased when used in combination with Metoclopramide.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Metoclopramide.Approved
RemifentanilThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Reserpine.Approved, Investigational
RevefenacinThe therapeutic efficacy of Revefenacin can be decreased when used in combination with Metoclopramide.Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ricolinostat.Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Rilpivirine.Approved
RimexoloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Rimexolone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Risperidone.Approved, Investigational
RisperidoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ritanserin.Investigational
RitobegronThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Ritobegron.Investigational
RitonavirThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Rivastigmine is combined with Metoclopramide.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Metoclopramide.Approved
RociverineThe therapeutic efficacy of Rociverine can be decreased when used in combination with Metoclopramide.Experimental
RocuroniumThe therapeutic efficacy of Rocuronium can be decreased when used in combination with Metoclopramide.Approved
RomidepsinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Romidepsin.Approved, Investigational
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Ronifibrate.Experimental
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Metoclopramide.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Rosoxacin.Approved, Investigational
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Rosuvastatin.Approved
RotigotineThe therapeutic efficacy of Rotigotine can be decreased when used in combination with Metoclopramide.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Roxithromycin.Approved, Investigational, Withdrawn
RP-5063The risk or severity of adverse effects can be increased when Metoclopramide is combined with RP-5063.Investigational
RufloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Rufloxacin.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Rupatadine.Approved
SafinamideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Safrazine.Withdrawn
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Metoclopramide.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Metoclopramide.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sarafloxacin.Vet Approved, Withdrawn
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Metoclopramide.Approved, Investigational
SecobarbitalThe therapeutic efficacy of Secobarbital can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Metoclopramide.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertindole.Approved, Investigational, Withdrawn
SertindoleThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertraline.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sevoflurane.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Metoclopramide is combined with Simfibrate.Experimental
SimvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Metoclopramide is combined with Simvastatin.Approved
SitafloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sitafloxacin.Experimental, Investigational
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Metoclopramide.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Metoclopramide.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sparfloxacin.Approved, Investigational
St. John's WortThe risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with Metoclopramide.Approved, Investigational, Nutraceutical
SuccinylcholineMetoclopramide may increase the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Sufentanil.Approved, Investigational
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Metoclopramide.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sultopride.Experimental
SultoprideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Metoclopramide.Approved, Investigational
SunitinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sunitinib.Approved, Investigational
TalbutalThe therapeutic efficacy of Talbutal can be decreased when used in combination with Metoclopramide.Approved, Illicit
TalinololMetoclopramide may increase the bradycardic activities of Talinolol.Investigational
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Metoclopramide.Approved
TandospironeThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Tandospirone.Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Tandutinib.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Metoclopramide.Approved
TD-8954The risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with TD-8954.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Technetium Tc-99m ciprofloxacin.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid phosphate is combined with Metoclopramide.Approved
TegaserodThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Tegaserod.Approved, Investigational, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Telavancin.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Temafloxacin.Withdrawn
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Metoclopramide.Approved
TerfenadineThe therapeutic efficacy of Terfenadine can be decreased when used in combination with Metoclopramide.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Terodiline.Experimental
TertatololMetoclopramide may increase the bradycardic activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrabenazine.Approved, Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrahydropalmatine.Investigational
ThiazinamThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiethylperazine.Withdrawn
ThiopentalThe therapeutic efficacy of Thiopental can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thioridazine.Approved, Withdrawn
ThioridazineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiothixene.Approved
ThiothixeneThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Thiothixene.Approved
ThonzylamineThe therapeutic efficacy of Thonzylamine can be decreased when used in combination with Metoclopramide.Approved
TiaprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tiapride.Approved, Investigational
Tiemonium iodideThe therapeutic efficacy of Tiemonium iodide can be decreased when used in combination with Metoclopramide.Experimental
TilidineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Tilidine.Experimental
TimepidiumThe therapeutic efficacy of Timepidium can be decreased when used in combination with Metoclopramide.Experimental
TimololMetoclopramide may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Metoclopramide.Approved
TixocortolThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Tixocortol.Approved, Withdrawn
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Metoclopramide.Approved, Investigational
ToloxatoneThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Toloxatone.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Metoclopramide.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metoclopramide.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Metoclopramide.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TridihexethylThe therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Metoclopramide.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Triflupromazine.Approved, Vet Approved
TriflupromazineThe therapeutic efficacy of Triflupromazine can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Metoclopramide.Approved
TrilostaneThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimebutineThe therapeutic efficacy of Trimebutine can be decreased when used in combination with Metoclopramide.Approved
TrimetazidineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimetazidine.Approved, Investigational
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Metoclopramide.Approved, Investigational
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Metoclopramide.Approved, Vet Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Triprolidine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Triptorelin.Approved, Vet Approved
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with Metoclopramide.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Metoclopramide.Approved, Investigational
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Metoclopramide.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Metoclopramide.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Tucidinostat.Investigational
UlobetasolThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Ulobetasol.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Metoclopramide.Approved
VabicaserinThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Vabicaserin.Investigational
Valproate bismuthThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Valproate bismuth.Approved
Valproic AcidThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Metoclopramide.Approved
VareniclineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Metoclopramide.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Veralipride.Experimental
VilanterolThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Metoclopramide.Approved
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Metoclopramide.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Vorinostat.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Metoclopramide.Approved, Investigational
YKP-1358The risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with YKP-1358.Investigational
YohimbineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Yohimbine.Approved, Investigational, Vet Approved
ZimelidineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.Approved
ZiprasidoneThe therapeutic efficacy of Ziprasidone can be decreased when used in combination with Metoclopramide.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Metoclopramide.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zotepine.Approved, Investigational, Withdrawn
ZotepineThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Food reduces availability, take 30 minutes before meals. Avoid alcohol.

References

Synthesis Reference
US3177252
General References
  1. JUSTIN-BESANCON L, LAVILLE C: [ANTIEMETIC ACTION OF METOCLOPRAMIDE WITH RESPECT TO APOMORPHINE AND HYDERGINE]. C R Seances Soc Biol Fil. 1964;158:723-7. [PubMed:14186927]
  2. Tonini M, Candura SM, Messori E, Rizzi CA: Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Pharmacol Res. 1995 May;31(5):257-60. [PubMed:7479521]
External Links
Human Metabolome Database
HMDB0015363
KEGG Drug
D00726
KEGG Compound
C07868
PubChem Compound
4168
PubChem Substance
46505631
ChemSpider
4024
BindingDB
48320
ChEBI
107736
ChEMBL
CHEMBL86
Therapeutic Targets Database
DAP000530
PharmGKB
PA450475
IUPHAR
241
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Metoclopramide
ATC Codes
A03FA01 — Metoclopramide
AHFS Codes
  • 56:32.00 — Prokinetic Agents
FDA label
Download (90.1 KB)
MSDS
Download (73.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticHemorrhage, Gastrointestinal1
1TerminatedBasic ScienceDrug Metabolism, Poor, CYP2D6-RELATED1
1, 2CompletedTreatmentEnteral Feeding Intolerance (EFI)1
1, 2CompletedTreatmentPost-Traumatic Headaches1
2CompletedPreventionOpioid Analgesic Adverse Reaction / Traumas1
2CompletedTreatmentDelayed Gastric Emptying / Diabetes Mellitus (DM) / Diabetic Gastroparesis / Gastroparesis1
2CompletedTreatmentEnteral Feeding Intolerance (EFI)1
2CompletedTreatmentInfant, Newborn, Diseases1
2CompletedTreatmentMigraine Disorders1
2CompletedTreatmentMigrainous Headache1
2Not Yet RecruitingPreventionPost Anaesthetic Shivering1
2Not Yet RecruitingTreatmentCritical Illness / Enteral Feeding Intolerance (EFI) / Nutrition, Enteral1
2RecruitingTreatmentNuclear radiation emergency / Nutrition, Enteral1
2TerminatedSupportive CareVomiting1
2TerminatedTreatmentBenign Headache1
2TerminatedTreatmentGastroparesis1
2WithdrawnTreatmentMyelodysplastic Syndromes1
2, 3WithdrawnTreatmentHeadaches1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentBreastfeeding1
3CompletedTreatmentClozapine-induced Hypersalivation1
3CompletedTreatmentElective Caesarean Section Surgeries1
3CompletedTreatmentHeadaches / Intranasal Ketamine1
3CompletedTreatmentMigraines1
3Enrolling by InvitationTreatmentAutonomic Nervous System Diseases / Dopamine Beta-Hydroxylase Deficiency / Idiopathic orthostatic hypotension / Orthostatic Intolerance1
3Not Yet RecruitingTreatmentAcute Gastroenteritis / Vomiting1
3RecruitingPreventionChemotherapy Induced Vomiting / Leukemia Acute Myeloid Leukemia (AML)1
3RecruitingTreatmentGastroschisis1
3RecruitingTreatmentHyperemesis Gravidarum1
3RecruitingTreatmentNausea / Vomiting1
3RecruitingTreatmentPost-Traumatic Headaches1
3RecruitingTreatmentTumors, Solid1
3TerminatedPreventionSepsis1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentVomiting1
3Unknown StatusDiagnosticHemorrhage, Gastrointestinal / Refractory Anemia / Small Bowel Diseases1
3Unknown StatusPreventionNausea / Vomiting1
3WithdrawnTreatmentMigraines1
4CompletedNot AvailablePill Capsule Endoscopy Completion Rates1
4CompletedPreventionInfants, Premature1
4CompletedPreventionMigraines1
4CompletedPreventionNausea / Satisfaction / Vomiting1
4CompletedPreventionPregnancy1
4CompletedPreventionProlonged First Stage of Labor1
4CompletedTreatmentHeadaches1
4CompletedTreatmentMigraine Disorders1
4CompletedTreatmentMigraine With Aura / Migraine Without Aura / Probable Migraine1
4CompletedTreatmentMigraine, Acute1
4CompletedTreatmentMigraines2
4CompletedTreatmentMigrainous Headache1
4CompletedTreatmentMigrainous Headache / Nausea / Restlessness1
4CompletedTreatmentNausea / Vertigo / Vomiting1
4CompletedTreatmentNausea / Vomiting1
4CompletedTreatmentExtra-pyramidal symptoms / Nausea1
4CompletedTreatmentOpioid Induced Pharyngeal and Esophageal Dysfunction1
4CompletedTreatmentPostoperative Function Level / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
4Not Yet RecruitingPreventionProphylaxis against postoperative nausea and vomiting1
4Not Yet RecruitingTreatmentCancers / Nausea / Vomiting1
4Not Yet RecruitingTreatmentReflux, Gastroesophageal1
4RecruitingPreventionLaparoscopic Sleeve Gastrectomy / Prophylaxis against postoperative nausea and vomiting1
4RecruitingTreatmentAcute Myocardial Infarction (AMI)1
4RecruitingTreatmentMigraines1
4RecruitingTreatmentOpiate withdrawal symptoms1
4RecruitingTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
4SuspendedTreatmentMigrainous Headache1
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedDiagnosticColorectal Cancer Screening1
Not AvailableCompletedDiagnosticGastric Transit Time1
Not AvailableCompletedPreventionAkathisia / Nausea1
Not AvailableCompletedPreventionCesarean Delivery1
Not AvailableCompletedPreventionHeadaches1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedTreatmentBreastfeeding1
Not AvailableCompletedTreatmentCancers1
Not AvailableNot Yet RecruitingTreatmentAssisted Reproductive Technology therapy / Poor Responder1
Not AvailableNot Yet RecruitingTreatmentPoor Responders in IVF1
Not AvailableRecruitingBasic ScienceHealth1
Not AvailableRecruitingTreatmentHigh Altitude Headache / Other and unspecified effects of high altitude1
Not AvailableRecruitingTreatmentMigrainous Headache1
Not AvailableTerminatedTreatmentFeeding Disorder / Infants, Premature / Nutrition Disorder1
Not AvailableTerminatedTreatmentNausea1
Not AvailableTerminatedTreatmentPrimary Headaches (Includes Migraines, Tension, Cluster Headaches)1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentPost Concussive Headache / Post Concussive Syndrome1
Not AvailableWithdrawnTreatmentPost Operative Nausea and Vomiting (PONV) / Rescue Emetic Therapy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Alaven Pharmaceutical
  • Almus Pharmaceuticals Usa LLC
  • Amerisource Health Services Corp.
  • Anip Acquisition Co.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Baxter International Inc.
  • Bay Pharma Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • General Injectables and Vaccines Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Innoviant Pharmacy Inc.
  • Ipca Laboratories Ltd.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Neighborcare Repackaging Inc.
  • Neuman Distributors Inc.
  • Northstar Rx LLC
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • Pharmaceutical Association
  • Pharmaceutical Packaging Center
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Piramal Healthcare
  • Pliva Inc.
  • Precision Dose Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Salix Pharmaceuticals
  • Sandhills Packaging Inc.
  • Sandoz
  • Silarx Pharmaceuticals
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Vangard Labs Inc.
  • Viasys Medsystems
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
  • Xactdose Inc.
Dosage forms
FormRouteStrength
LiquidOral1 mg
InjectionIntramuscular; Intravenous5 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/2mL
Injection, solutionIntramuscular; Intravenous5 mg/mL
SolutionOral10 mg/10mL
SolutionOral5 mg/5mL
TabletOral10 mg/1
TabletOral5 mg/1
Injection, solutionIntravenous5 mg/mL
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral5 mg/1
LiquidIntramuscular; Intravenous5 mg
LiquidIntravenous5 mg
SolutionOral5 mg
TabletOral10 mg
TabletOral5 mg
SyrupOral1 mg
Prices
Unit descriptionCostUnit
Metoclopramide hcl powder7.65USD g
Reglan 10 mg tablet1.81USD tablet
Reglan 5 mg tablet1.41USD tablet
Metoclopramide Hydrochloride 5 mg/ml1.39USD ml
Reglan 5 mg/ml vial0.56USD ml
Metoclopramide HCl 5 mg tablet0.43USD tablet
Metoclopramide 5 mg tablet0.33USD tablet
Metoclopramide 10 mg tablet0.28USD tablet
Metoclopramide 5 mg/ml ampul0.28USD ml
Metoclopramide HCl 10 mg tablet0.27USD tablet
Metoclopramide HCl 5 mg/5ml Solution0.06USD ml
Apo-Metoclop 10 mg Tablet0.06USD tablet
Apo-Metoclop 5 mg Tablet0.06USD tablet
Nu-Metoclopramide 10 mg Tablet0.06USD tablet
Nu-Metoclopramide 5 mg Tablet0.06USD tablet
Pms-Metoclopramide 10 mg Tablet0.06USD tablet
Pms-Metoclopramide 5 mg Tablet0.06USD tablet
Pms-Metoclopramide 1 mg/ml Liquid0.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6221392No1998-04-092018-04-09Us
US6024981No1998-04-092018-04-09Us
US6413549No1997-07-112017-07-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)147.25 °CPhysProp
water solubility200 mg/L (at 25 °C)MERCK (1989)
logP2.62HANSCH,C ET AL. (1995)
logS-3.18ADME Research, USCD
pKa9.27 (at 25 °C)EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.31 mg/mLALOGPS
logP2.18ALOGPS
logP1.4ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)14.49ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.59 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity83.52 m3·mol-1ChemAxon
Polarizability32.7 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.979
Blood Brain Barrier+0.9713
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.7687
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8783
Renal organic cation transporterNon-inhibitor0.7276
CYP450 2C9 substrateNon-substrate0.8602
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6375
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9099
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6223
Ames testNon AMES toxic0.5378
CarcinogenicityNon-carcinogens0.6142
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6332 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Inhibitor0.8579
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0090000000-10fdf9db1550886fc034
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-fcc278321866ecdee26f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0193000000-c044c04d9d51d66ba5a9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0290000000-45d3c52d766c4cd8ae93
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-003r-0970000000-2f2d709cad2c27f798e5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0920000000-ccce0f42f04edf0ecfb3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0900000000-93aec7dddb8a098f7483
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-e7b25ddf867c24be5347
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0093000000-dc0ce524de60c6a189a7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0290000000-2bca02d9f4cee5acca4e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-003r-0970000000-50fe530dffb9aa59d433
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0920000000-0bb9973fdbe0820dc3d1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0900000000-4cc6fae9bec9d4c40dbb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0090000000-1c4a27b221c7a053d2c3
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fb9-0595000000-db3b50f051cfcc835a69

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminophenyl ethers. These are aromatic compounds that contain a phenol ether, which carries an amine group on the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Aminophenyl ethers
Direct Parent
Aminophenyl ethers
Alternative Parents
Methoxyanilines / Phenoxy compounds / Methoxybenzenes / Anisoles / Chlorobenzenes / Alkyl aryl ethers / Aryl chlorides / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids
show 4 more
Substituents
Aminophenyl ether / Methoxyaniline / Phenoxy compound / Anisole / Methoxybenzene / Aniline or substituted anilines / Alkyl aryl ether / Chlorobenzene / Halobenzene / Aryl chloride
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, substituted aniline, benzamides, monochlorobenzenes (CHEBI:107736)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. See RE, Lynch AM, Sorg BA: Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats. Neuroscience. 1996 May;72(1):99-104. [PubMed:8730709]
  3. Harrold MW, Sriburi A, Matsumoto K, Miller DD, Farooqui T, Uretsky N: The interaction of ammonium, sulfonium, and sulfide analogues of metoclopramide with the dopamine D2 receptor. J Med Chem. 1993 Oct 15;36(21):3166-70. [PubMed:8230103]
  4. Kishibayashi N, Karasawa A: Stimulating effects of KW-5092, a novel gastroprokinetic agent, on the gastric emptying, small intestinal propulsion and colonic propulsion in rats. Jpn J Pharmacol. 1995 Jan;67(1):45-50. [PubMed:7745844]
  5. Chemnitius JM, Haselmeyer KH, Gonska BD, Kreuzer H, Zech R: Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood. Pharmacol Res. 1996 Jul-Aug;34(1-2):65-72. [PubMed:8981558]
  6. Dahlof CG, Hargreaves RJ: Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies? Cephalalgia. 1998 Nov;18(9):593-604. [PubMed:9876882]
  7. Hammer D: Gastroesophageal reflux and prokinetic agents. Neonatal Netw. 2005 Mar-Apr;24(2):51-8; quiz 59-62. [PubMed:15835479]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Burger DM, Wiestner T, Hubler M, Binder H, Keiser M, Arnold S: Effect of anticholinergics (atropine, glycopyrrolate) and prokinetics (metoclopramide, cisapride) on gastric motility in beagles and labrador retrievers. J Vet Med A Physiol Pathol Clin Med. 2006 Mar;53(2):97-107. [PubMed:16466463]
  4. Hammer D: Gastroesophageal reflux and prokinetic agents. Neonatal Netw. 2005 Mar-Apr;24(2):51-8; quiz 59-62. [PubMed:15835479]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR4
Uniprot ID
Q13639
Uniprot Name
5-hydroxytryptamine receptor 4
Molecular Weight
43760.975 Da
References
  1. Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, Lihrmann I, Pichon P, Thuillez C, Plouin PF, Bertherat J, Anouar Y, Kuhn JM, Yon L, Lefebvre H: Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer. 2009 Mar;16(1):281-90. doi: 10.1677/ERC-08-0190. Epub 2008 Oct 23. [PubMed:18948374]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Costall B, Gunning SJ, Naylor RJ, Tyers MB: The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig. Br J Pharmacol. 1987 Jun;91(2):263-4. [PubMed:2955843]
Details
5. Acetylcholinesterase
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
reversible inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Petroianu G, Arafat K, Kosanovic M, Saleh A, Camasamudram V, Hasan MY: In vitro protection of red blood cell acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox). J Appl Toxicol. 2003 Nov-Dec;23(6):447-51. [PubMed:14635269]

Enzymes

Details
1. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 17-alpha-monooxygenase activity
Specific Function
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation ...
Gene Name
CYP17A1
Uniprot ID
P05093
Uniprot Name
Steroid 17-alpha-hydroxylase/17,20 lyase
Molecular Weight
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 10:01